纳洛酮联合亚低温冬眠疗法治疗弥漫性轴索损伤的可行性分析

Feasibility analysis of naloxone combined with mild hypothermia hibernation therapy for diffuse axonal injury

目的探讨纳洛酮联合亚低温冬眠疗法治疗弥漫性轴索损伤(DAI)的临床疗效及安全性。方法将GOS评分<8分的80例DAI患者随机分为对照组与治疗组,各40例。两组均接受常规治疗,而治疗组在此基础上再加以纳洛酮联合亚低温冬眠疗法治疗,比较两组恢复良好率、死亡率以及并发症发生率。结果治疗组的恢复良好率为57.5%,死亡率为12.5%,对照组分别为32.5%、40.0%,组间比较有明显差异(P<0.05);两组DAI患者的并发症发生率无明显差异(P>0.05)。结论纳洛酮联合亚低温冬眠疗法治疗DAI,可行性高,可明显提高患者的恢复良好率,且并未明显增加并发症。

Objective To observe the clinical efficacy and safety of naloxone combined with mild hypothermia hibernation therapy for treatment of diffuse axonal injury （DAI）. Methods Eighty cases of DAI patients with GOS score lower than 8 were randomly divided into control group and treatment group. Both groups were treated with conventional therapy. Based on this, the treatment group received naloxone combined with mild hypothermia hibernation therapy. The recovery rate, death rate and complications were compared. Results The recovery rate and death rate in treatment group were 57.5% and 12.5% respectively, and 32.5% and 40.0% in the control group. The differences were both statistically significant （P 〈0.05）; The incidence rate of complications in the two groups had no significant difference （P〉0.05）. Conclusion Naloxone combined with mild hypothermia hibernation therapy is of high feasibility, and can significantly improve the recovery rate with no obvious increasing in complications.